Immunisation, Hepatitis and Blood Safety Department, Health Protection Services Colindale, Health Protection Agency, 61 Colindale Ave., London, UK.
Epidemiol Infect. 2012 Oct;140(10):1830-7. doi: 10.1017/S0950268811002317. Epub 2011 Nov 29.
In a cohort of 272 treatment-naive individuals with chronic hepatitis C infection acquired on a known date who were enrolled in the UK HCV National Register, a progressive improvement in response to treatment was found with the evolution of antiviral therapies from 20% (25/122) for interferon monotherapy to 63% (55/88) for pegylated interferon+ribavirin therapy. Multivariable analysis results showed increasing age to be associated with poorer response to therapy [odds ratio (OR) 0·84, 95% confidence interval (CI) 0·72-0·99, P=0·03] whereas time since infection was not associated with response (OR 0·93, 95% CI 0·44-1·98, P=0·85). Other factors significantly associated with a positive response were non-type 1 genotype (P<0·0001) and combination therapies (P<0·0001). During the first two decades of chronic HCV infection, treatment at a younger age was found to be more influential in achieving a sustained viral response than treating earlier in the course of infection.
在英国 HCV 国家登记处登记的一组已知日期感染慢性丙型肝炎病毒的 272 名未经治疗的个体中，随着抗病毒治疗方法从干扰素单一疗法的 20%（25/122）发展到聚乙二醇干扰素+利巴韦林疗法的 63%（55/88），发现治疗反应逐渐改善。多变量分析结果表明，年龄越大，治疗反应越差[比值比（OR）0.84，95%置信区间（CI）0.72-0.99，P=0.03]，而感染后时间与反应无关（OR 0.93，95% CI 0.44-1.98，P=0.85）。与阳性反应显著相关的其他因素是非 1 型基因型（P<0.0001）和联合疗法（P<0.0001）。在慢性丙型肝炎感染的头二十年中，发现年轻时接受治疗比在感染早期接受治疗更能实现持续病毒应答。
